GlassScriptPhysician profile
Michael B Fischer
NPI 1114913779
$5,087.84
in general payments reported to CMS, 2019-2025
31 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $244 · 2021: $1,041 · 2022: $623 · 2023: $564 · 2024: $889 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $901.94 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $507.90 | 2019-2022 | |
| Amgen INC. | $493.70 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $425.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $403.07 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $381.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $366.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $197.44 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $191.33 | 2019-2025 | Zoryve |
| Pfizer INC. | $178.30 | 2019-2022 | |
| Exact Sciences Corporation | $152.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $150.51 | 2019-2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $105.03 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $101.11 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.42 | 2021-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.26 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $50.74 | 2024 | |
| Allergan, INC. | $47.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.89 | 2024 | |
| Lundbeck LLC | $43.63 | 2025 | Rexulti |
| Arbor Pharmaceuticals, INC. | $32.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.39 | 2019-2020 | |
| Corcept Therapeutics | $26.02 | 2024 | Korlym |
| Shire North American Group INC | $17.57 | 2019 | |
| Althera Pharmaceuticals LLC | $17.34 | 2021 | |
| Medicomp INC | $16.52 | 2025 | Telepatch Cardiac Monitor |
| Seqirus USA INC | $16.17 | 2019 | |
| Boston Scientific Corporation | $15.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.